1. Home
  2. PRFX vs XAIR Comparison

PRFX vs XAIR Comparison

Compare PRFX & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PainReform Ltd.

PRFX

PainReform Ltd.

HOLD

Current Price

$0.88

Market Cap

2.6M

Sector

Health Care

ML Signal

HOLD

Logo Beyond Air Inc.

XAIR

Beyond Air Inc.

SELL

Current Price

$2.59

Market Cap

3.0M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
PRFX
XAIR
Founded
2007
2011
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6M
3.0M
IPO Year
2020
2015

Fundamental Metrics

Financial Performance
Metric
PRFX
XAIR
Price
$0.88
$2.59
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $20.00
AVG Volume (30 Days)
★ 258.6K
60.4K
Earning Date
09-03-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $7,679,000.00
Revenue This Year
N/A
$4.23
Revenue Next Year
N/A
$108.84
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 107.26
52 Week Low
$0.58
$0.33
52 Week High
$5.39
$8.19

Technical Indicators

Market Signals
Indicator
PRFX
XAIR
Relative Strength Index (RSI) 38.52 35.95
Support Level $0.60 $2.38
Resistance Level $1.25 $2.66
Average True Range (ATR) 0.09 0.23
MACD -0.00 0.03
Stochastic Oscillator 2.06 27.73

Price Performance

Historical Comparison
PRFX
XAIR

About PRFX PainReform Ltd.

PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasize reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the company's lead product, is based on the local anesthetic ropivacaine and targets the postoperative pain relief market. The company has two operating segments composed of the Clinical Development segment, which facilitates the development of potential new drug compounds, and the Solar segment, which comprises the design and development of the company's intellectual property and the sale related service offerings.

About XAIR Beyond Air Inc.

Beyond Air Inc a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems (the LungFit platform) capable of generating NO from ambient air. Its segments are Beyond Air, Beyond Cancer, and NeuroNos. The company generates majority of revenue from Beyond Air. It has developed the Beyond Air NO generator and delivery system which it call LungFit, a novel and precise delivery system that uses NO generated from ambient air with a novel NO generator, the ionizer. Its product and technology includes LungFitPH.

Share on Social Networks: